GB2516808A - Antibody composition and buffer system therefor - Google Patents

Antibody composition and buffer system therefor Download PDF

Info

Publication number
GB2516808A
GB2516808A GB1309759.7A GB201309759A GB2516808A GB 2516808 A GB2516808 A GB 2516808A GB 201309759 A GB201309759 A GB 201309759A GB 2516808 A GB2516808 A GB 2516808A
Authority
GB
United Kingdom
Prior art keywords
buffer
antibody
pka
acid
glycine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1309759.7A
Other languages
English (en)
Other versions
GB201309759D0 (en
Inventor
Bianca Fusetti
Nick Gee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innova Biosciences Ltd
Original Assignee
Innova Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innova Biosciences Ltd filed Critical Innova Biosciences Ltd
Priority to GB1309759.7A priority Critical patent/GB2516808A/en
Publication of GB201309759D0 publication Critical patent/GB201309759D0/en
Priority to GB1522774.7A priority patent/GB2530217A/en
Priority to EP14730479.4A priority patent/EP3003385B1/en
Priority to DK14730479.4T priority patent/DK3003385T3/da
Priority to PCT/EP2014/061281 priority patent/WO2014191560A1/en
Priority to JP2016516187A priority patent/JP2016530216A/ja
Priority to CN201480043061.4A priority patent/CN105592860B/zh
Priority to AU2014273034A priority patent/AU2014273034B2/en
Priority to US14/894,828 priority patent/US11046753B2/en
Priority to ES14730479T priority patent/ES2762501T3/es
Publication of GB2516808A publication Critical patent/GB2516808A/en
Priority to JP2019163553A priority patent/JP2020007343A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
GB1309759.7A 2013-05-31 2013-05-31 Antibody composition and buffer system therefor Withdrawn GB2516808A (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
GB1309759.7A GB2516808A (en) 2013-05-31 2013-05-31 Antibody composition and buffer system therefor
ES14730479T ES2762501T3 (es) 2013-05-31 2014-05-30 Composición de anticuerpo y sistema amortiguador para la misma
PCT/EP2014/061281 WO2014191560A1 (en) 2013-05-31 2014-05-30 Antibody composition and buffer system therefor
EP14730479.4A EP3003385B1 (en) 2013-05-31 2014-05-30 Antibody composition and buffer system therefor
DK14730479.4T DK3003385T3 (da) 2013-05-31 2014-05-30 Antistofsammensætning og buffersystem til denne
GB1522774.7A GB2530217A (en) 2013-05-31 2014-05-30 Antibody composition and buffer system therefor
JP2016516187A JP2016530216A (ja) 2013-05-31 2014-05-30 抗体組成物及びそのための緩衝系
CN201480043061.4A CN105592860B (zh) 2013-05-31 2014-05-30 抗体组合物和用于其的缓冲体系
AU2014273034A AU2014273034B2 (en) 2013-05-31 2014-05-30 Antibody composition and buffer system therefor
US14/894,828 US11046753B2 (en) 2013-05-31 2014-05-30 Antibody composition and buffer system therefor
JP2019163553A JP2020007343A (ja) 2013-05-31 2019-09-09 抗体組成物及びそのための緩衝系

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1309759.7A GB2516808A (en) 2013-05-31 2013-05-31 Antibody composition and buffer system therefor

Publications (2)

Publication Number Publication Date
GB201309759D0 GB201309759D0 (en) 2013-07-17
GB2516808A true GB2516808A (en) 2015-02-11

Family

ID=48805557

Family Applications (2)

Application Number Title Priority Date Filing Date
GB1309759.7A Withdrawn GB2516808A (en) 2013-05-31 2013-05-31 Antibody composition and buffer system therefor
GB1522774.7A Withdrawn GB2530217A (en) 2013-05-31 2014-05-30 Antibody composition and buffer system therefor

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB1522774.7A Withdrawn GB2530217A (en) 2013-05-31 2014-05-30 Antibody composition and buffer system therefor

Country Status (9)

Country Link
US (1) US11046753B2 (enExample)
EP (1) EP3003385B1 (enExample)
JP (2) JP2016530216A (enExample)
CN (1) CN105592860B (enExample)
AU (1) AU2014273034B2 (enExample)
DK (1) DK3003385T3 (enExample)
ES (1) ES2762501T3 (enExample)
GB (2) GB2516808A (enExample)
WO (1) WO2014191560A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170189548A1 (en) * 2015-11-25 2017-07-06 Immunogen, Inc. Pharmaceutical formulations and methods of use thereof
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
CN111896752A (zh) * 2020-08-11 2020-11-06 上海捷门生物技术有限公司 一种适用于多种poct类仪器的c-反应蛋白试剂盒
CN113671188A (zh) * 2021-08-10 2021-11-19 江南大学 一种检测贝类食品中河豚毒素的时间分辨免疫定量试纸条
EP4218562A1 (en) 2022-01-28 2023-08-02 Charité - Universitätsmedizin Berlin Real-time breath antigen detection system and method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0988861A1 (en) * 1998-08-17 2000-03-29 Pfizer Products Inc. Stabilized protein compositions
WO2006112838A1 (en) * 2005-04-18 2006-10-26 Xtl Biopharmaceuticals Ltd. Stabilized anti-hepatitis b (hbv) antibody formulations
WO2008079290A2 (en) * 2006-12-21 2008-07-03 Amgen Inc Stable buffered formulations containing polypeptides
EP1977763A1 (en) * 2005-12-28 2008-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody-containing stabilizing preparation
EP2380593A1 (en) * 2010-04-23 2011-10-26 Arkray, Inc. Stabilizing labeled antibody using amino acids

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0516873A1 (en) 1991-06-06 1992-12-09 THE STATE of ISRAEL Atomic Energy Commission Soreq Nuclear Research Center A method and kit for protein labelling with 99 mTC
AU2006295340B2 (en) 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
CN101330931B (zh) * 2005-12-12 2012-09-05 创新生物科学有限公司 制备缀合物
CN102089662B (zh) 2008-07-16 2015-05-27 雷迪奥米特医学公司 高容量固相
EP2583973B1 (en) 2010-06-21 2018-03-21 Kyowa Hakko Kirin Co., Ltd. Method for purifying protein using amino acid
US8877892B2 (en) * 2011-03-15 2014-11-04 Innova Biosciences Limited Conjugation reactions
EP2686334B2 (en) 2011-03-16 2020-07-01 F.Hoffmann-La Roche Ag Ion exchange chromatography with improved selectivity for the separation of polypeptide monomers, aggregates and fragments by modulation of the mobile phase
KR20120128440A (ko) 2011-05-17 2012-11-27 삼성전자주식회사 표적 물질 검출용 키트 및 이를 이용한 표적 물질 검출 방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0988861A1 (en) * 1998-08-17 2000-03-29 Pfizer Products Inc. Stabilized protein compositions
WO2006112838A1 (en) * 2005-04-18 2006-10-26 Xtl Biopharmaceuticals Ltd. Stabilized anti-hepatitis b (hbv) antibody formulations
EP1977763A1 (en) * 2005-12-28 2008-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody-containing stabilizing preparation
WO2008079290A2 (en) * 2006-12-21 2008-07-03 Amgen Inc Stable buffered formulations containing polypeptides
EP2380593A1 (en) * 2010-04-23 2011-10-26 Arkray, Inc. Stabilizing labeled antibody using amino acids

Also Published As

Publication number Publication date
GB201309759D0 (en) 2013-07-17
GB201522774D0 (en) 2016-02-03
US11046753B2 (en) 2021-06-29
WO2014191560A1 (en) 2014-12-04
AU2014273034B2 (en) 2019-11-21
JP2016530216A (ja) 2016-09-29
ES2762501T8 (es) 2020-06-18
JP2020007343A (ja) 2020-01-16
US20160122416A1 (en) 2016-05-05
ES2762501T3 (es) 2020-05-25
AU2014273034A1 (en) 2016-01-28
CN105592860B (zh) 2021-02-02
EP3003385B1 (en) 2019-09-18
GB2530217A (en) 2016-03-16
EP3003385A1 (en) 2016-04-13
DK3003385T3 (da) 2020-01-06
CN105592860A (zh) 2016-05-18

Similar Documents

Publication Publication Date Title
DeLuca-Flaherty et al. Uncoating protein (hsc70) binds a conformationally labile domain of clathrin light chain LCa to stimulate ATP hydrolysis
EP3003385B1 (en) Antibody composition and buffer system therefor
Landi et al. Synthesis and application of a new cleavable linker for “click”-based affinity chromatography
JPH02133469A (ja) 求核性多置換アリールアクリジニウムエステルとその製造方法およびそれを用いたアッセイ
CN110849694B (zh) 一种他克莫司全血样本前处理液及其使用方法和应用
EP3314616B1 (en) Entrapment of magnetic nanoparticles in a cross-linked protein matrix without affecting the functional properties of the protein
JP7691701B2 (ja) 金属錯体試薬を介するＨｉｓタグ付タンパク質などの標的分子への標識および／または担体の部位特異的、速度論的に不活性なコンジュゲーション
US20040146950A1 (en) Phosphoprotein detection reagent and methods of making and using the same
JP2013526701A (ja) 結合系
Xu et al. A facile method to oriented immobilization of His-tagged BirA on Co3+-NTA agarose beads
JPH03502487A (ja) 同一性および出所を確認するための化学物品の標識
CN112285345B (zh) 甘胆酸检测试剂盒
JP6867289B2 (ja) 合成ビエピトープ化合物
CN110954707B (zh) 丙戊酸衍生物及其在免疫检测中的用途
Ślósarczyk et al. The molecular recognition of phosphorylated proteins by designed polypeptides conjugated to a small molecule that binds phosphate
US20110008811A1 (en) Resin Assisted Capture of Cysteine-Modified Proteins/Peptides and Determination of Presence and Location of Modification
Griffith et al. A highly efficient preparative-scale generic immunoaffinity chromatography method for the purification of antibodies to hydrophobic haptens: Purification procedure and monitoring tests
WO2025142873A1 (ja) 被検物質の検出方法、並びに、それに用いる標識用バッファー及びキット
WO2025121429A1 (ja) Ｆｃ－細胞複合体およびその製造方法
Anderson et al. Biotin derivatives of D-Phe-Pro-Arg-CH2Cl for active-site-specific labeling of thrombin and other serine proteinases
US20070021594A1 (en) Ligand-binding reagents for quenching and improved purification of lipidated proteins
Xu et al. Bivalent Homo-and Hetero-Nanobody-Based Immunoassays for The Analysis of the Disinfectant Triclosan in Water
CA2415158A1 (en) Biologically active protein conjugates formed by first protecting activesite
Huque Nuclear magnetic resonance studies of calmodulin

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)